Profil bibliographique

Dax Torti

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

243Publications signalées

1340Citations signalées

0Affiliations récentes

Les domaines associés

Cancer Genomics and DiagnosticsPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Les publications récentes

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Table S5: Novel pathogenic mutations discovered in cfDNA. List of novel pathogenic mutations found in cfDNA samples that were not detected in the bulk tumour tissue by whole exome sequencing. For each mutation, both the variant allele frequency (VAF), median fragment …

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Table S3: Targeted Sequencing Panel. List of regions included in the CHARM+EVOLVE panel used for targeted sequencing; coordinates are for human reference hg38.

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Figure 2: Estimated tumour content in plasma DNA

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S6 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Figure 6: Visualization of structural variants in cfDNA

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Figure 3: Distribution of ctDNA levels and statistical association with clinical features

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Figure 5: Sensitivity of variant calling methods on cfDNA

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S7 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Figure 7: Copy-number profile of CCNE1 in cfDNA

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Figure 4: Distribution of cfDNA fragment length

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Table S4: Targeted Lesions at Baseline. The baseline sum of targeted lesions (mm) for each patient, determined at baseline by CT for RECIST1.1 evaluation.

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Table S1: Representativeness of Study Participants

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo González-Ochoa et autres

Supplementary Figure 1: Establishment of limit of detection (LOD) for targeted sequencing panel on ctDNA

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.